OKYO Pharma Ltd
urcosimod
neuropathic corneal pain (NCP)
Resolved
160days ago
Advisory committee · Jan 28, 2026
What's at stake
An FDA advisory committee reviews urcosimod for neuropathic corneal pain (NCP) around Jan 28, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 14h ago
“On January 28, 2026, we announced a successful Type C meeting with the FDA, where the agency confirmed our proposed Phase 2b/3 clinical trial design for urcosimod in NCP.”